The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The mutational landscape of lethal castration-resistant prostate cancer
Open accessAbstract
Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC). However, less is known about the role of mutations. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,232
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897
Self-citationYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citationWang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 689
Self-citationGenome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
Cited by
Sorted by citations
Items 501–600 of 1,005
Woodcock, D. J., Рябченко, Е. В., Taavitsainen, S., Kankainen, M., Gundem, G., Brewer, D. S., Ellonen, P., Lepistö, M., Golubeva, Y. A., Warner, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18843-5 · Cited by 71
Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis
Tao, T., Chen, M., Jiang, R., Guan, H., Huang, Y., Su, H., Hu, Q., Han, X., & Xiao, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5430 · Cited by 70
A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer
Good, C. R., Madžo, J., Patel, B. G., Maegawa, S., Engel, N., Jelı́nek, J., & Issa, J. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx435 · Cited by 74
PGC1α Suppresses Prostate Cancer Cell Invasion through ERRα Transcriptional Control
Valcárcel-Jiménez, L., Macchia, A., Crosas‐Molist, E., Schaub-Clerigué, A., Camacho, L., Martín-Martín, N., Cicogna, P., Viera-Bardón, C., Fernández‐Ruiz, S., Rodríguez‐Hernández, I., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1231 · Cited by 73
Zhang, S., Dong, X., Ji, T., Chen, G., & Shan, L. (2017) · Europe PMC (PubMed Central) · Cited by 70
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma
Maitituoheti, M., Keung, E. Z.-Y., Tang, M., Liang, Y., Alam, H., Han, G., Singh, A. K., Raman, A. T., Terranova, C. J., Sarkar, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108293 · Cited by 71
Unno, K., Chalmers, Z. R., Pamarthy, S., Vatapalli, R. J., Rodríguez, Y., Lysy, B., Mok, H., Sagar, V., Han, H., Yoo, Y. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3351 · Cited by 70
Dhar, S. S., & Lee, M. G. (2021) · Oncotarget · doi:10.18632/oncotarget.27988 · Cited by 73
Non‐invasive detection of genome‐wide somatic copy number alterations by liquid biopsies
Heitzer, E., Ulz, P., Geigl, J. B., & Speicher, M. R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.004 · Cited by 71
Lee, Y. G., Nam, Y., Shin, K. J., Yoon, S., Park, W. S., Joung, J. Y., Seo, J. K., Jang, J., Lee, S., Nam, D., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.017 · Cited by 70
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
Zhou, S., Hawley, J. R., Soares, F., Grillo, G., Teng, M., Tonekaboni, S. A. M., Hua, J. T., Kron, K. J., Mazrooei, P., Ahmed, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14318-9 · Cited by 69
Androgen receptor mutations for precision medicine in prostate cancer
Shiota, M., Akamatsu, S., Tsukahara, S., Nagakawa, S., Matsumoto, T., & Eto, M. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0140 · Cited by 69
Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer
Lucarelli, G. T., Rutigliano, M., Galleggiante, V., Giglio, A., Palazzo, S., Ferro, M., Simone, C., Bettocchi, C., Battaglia, M., & Ditonno, P. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1069711 · Cited by 70
Royo, F., Zúñiga-García, P., Torrano, V., Loizaga‐Iriarte, A., Sánchez‐Mosquera, P., Ugalde‐Olano, A., González, E., Cortázar, A. R., Palomo, L., Fernández‐Ruiz, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6899 · Cited by 71
Yu, S., Huang, S., Ding, Y., Wang, W., Wang, A., & Lu, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1708-9 · Cited by 71
Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations
Yang, F., Petsalaki, E., Rolland, T., HILL, D. E., Vidal, M., & Roth, F. P. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004147 · Cited by 71
Epigenetic Regulation in Prostate Cancer Progression
Ruggero, K., Farran-Matas, S., Martínez-Tébar, A., & Aytés, À. (2018) · Current Molecular Biology Reports · doi:10.1007/s40610-018-0095-9 · Cited by 69
Spinella, J.-F., Mehanna, P., Vidal, R. O., Saillour, V., Cassart, P., Richer, C., Ouimet, M., Healy, J., & Sinnett, D. (2016) · BMC Genomics · doi:10.1186/s12864-016-3281-2 · Cited by 71
Zhang, K., Zhao, H., Ji, Z., Zhang, C., Zhou, P., Wang, L., Chen, Q., Wang, J., Zhang, P., Chen, Z., et al. (2015) · Oncogene · doi:10.1038/onc.2015.184 · Cited by 67
The genomic evolution of human prostate cancer
Mitchell, T. J., & Neal, D. E. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.234 · Cited by 68
Interplay of estrogen receptors and FOXA factors in the liver cancer
Zhao, Y., & Li, Z. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.043 · Cited by 69
Gupta, S. K., Li, J., Kemeny, G., Bitting, R. L., Beaver, J., Somarelli, J. A., Ware, K. E., Gregory, S. G., & Armstrong, A. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1211 · Cited by 69
Brechka, H., Bhanvadia, R. R., VanOpstall, C., & Griend, D. J. V. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.01.003 · Cited by 67
Hwang, J. H., Seo, J.-H., Beshiri, M. L., Wankowicz, S. A. M., Liu, D., Cheung, A. T. M., Li, J., Qiu, X., Hong, A. L., Botta, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.068 · Cited by 68
Lotan, T. L., Tomlins, S. A., Bismar, T. A., van der Kwast, T., Grignon, D. J., Egevad, L., Kristiansen, G., Pritchard, C. C., Rubin, M. A., & Bubendorf, L. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001450 · Cited by 67
Self-citationMcDaniel, A. S., Ferraldeschi, R., Krupa, R., Landers, M. A., Graf, R. P., Louw, J. E., Jendrisak, A., Bales, N., Marrinucci, D. C., Zafeiriou, Z., et al. (2016) · British Journal of Urology · doi:10.1111/bju.13631 · Cited by 66
Self-citationImamura, J., Ganguly, S., Muskara, A., Liao, R. S., Nguyen, J., Weight, C., Wee, C. E., Gupta, S., & Mian, O. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1191311 · Cited by 66
A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer
Stegeman, S., Moya, L., Selth, L. A., Spurdle, A. B., Clements, J. A., & Batra, J. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0013 · Cited by 66
Organoid development in cancer genome discovery
Gao, D., & Chen, Y. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.02.007 · Cited by 71
Mukherji, D., Omlin, A. G., Pezaro, C. J., Shamseddine, A. I., & Bono, J. S. D. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9473-1 · Cited by 66
STAMP2 increases oxidative stress and is critical for prostate cancer
Jin, Y., Wang, L., Qu, S., Sheng, X., Kristian, A., Mælandsmo, G. M., Pällmann, N., Yuca, E., Tekedereli, İ., Görgülü, K., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404181 · Cited by 66
Wang, L., Wang, J., Xiong, H., Wu, F., Lan, T., Zhang, Y., Guo, X., Wang, H., Saleem, M., Jiang, C., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.022 · Cited by 66
Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer
Gorchakov, A. A., Kulemzin, S. V., Kochneva, G. V., & Taranin, A. V. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.014 · Cited by 66
Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 65
Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway
P, P. S., Arthiga, K., Patil, A. B., Spandana, K. M. A., & Jain, V. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07369-2 · Cited by 66
Hsieh, C.-L., Botta, G., Gao, S., Li, T., Allen, E. M. V., Treacy, D. J., Cai, C., He, H. H., Sweeney, C. J., Brown, M. A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3602 · Cited by 65
A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer
Stegeman, S., Amankwah, E. K., Klein, K., O’Mara, T. A., Kim, D., Lin, H., Permuth‐Wey, J., Sellers, T. A., Srinivasan, S., Eeles, R. A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1057 · Cited by 65
Dai, H., Hu, W., Zhang, L., Jiang, F., Mao, X., Yang, G., & Li, L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03588-w · Cited by 65
The Role of Additional Sex Combs-Like Proteins in CancerPreprint
Micol, J., & Abdel-Wahab, O. I. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026526 · Cited by 65
Sentinels of chromatin: chromodomain helicase DNA-binding proteins in development and diseasePreprint
Alendar, A., & Berns, A. J. M. (2021) · Genes & Development · doi:10.1101/gad.348897.121 · Cited by 69
PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
Virtanen, V., Paunu, K., Ahlskog, J. K., Várnai, R., Sipeky, C., & Sundvall, M. (2019) · Genes · doi:10.3390/genes10080565 · Cited by 67
Therapy escape mechanisms in the malignant prostate
Santer, F. R., Erb, H. H. H., & McNeill, R. V. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.005 · Cited by 67
O ‐Glycosylation‐mediated signaling circuit drives metastatic castration‐resistant prostate cancer
Tzeng, S., Tsai, C., Chao, T., Chou, Y., Yang, Y., Tsai, M., Cha, T., & Hsiao, P. (2018) · The FASEB Journal · doi:10.1096/fj.201800687 · Cited by 64
Chang, Y.-T., Lin, T.-P., Tang, J.-T., Campbell, M., Luo, Y.-L., Lu, S.-Y., Yang, C.-P., Cheng, T.-Y., Chang, C.-H., Liu, T.-T., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.029 · Cited by 64
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Rodrigues, D. N., Casiraghi, N. A., Romanel, A., Crespo, M., Miranda, S., Rescigno, P., Figueiredo, I., Riisnaes, R., Carreira, S., Sumanasuriya, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2068 · Cited by 64
Pak, S., Park, S., Kim, Y., Park, J., Park, C. H., Lee, K.-J., Kim, C., & Ahn, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1342-5 · Cited by 65
Seshacharyulu, P., Rachagani, S., Muniyan, S., Siddiqui, J. A., Cruz, E., Sharma, S., Krishnan, R., Killips, B. J., Sheinin, Y. M., Lele, S. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0791-9 · Cited by 63
Self-citationZeuschner, P., Linxweiler, J., & Junker, K. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1665998 · Cited by 63
Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression
Saraon, P., Trudel, D., Kron, K. J., Dmitromanolakis, A., Trachtenberg, J., Bapat, B. V., van der Kwast, T., Jarvi, K. A., & Diamandis, E. P. (2013) · The Prostate · doi:10.1002/pros.22758 · Cited by 63
Bizzarro, V., Belvedere, R., Milone, M. R., Pucci, B., Lombardi, R., Bruzzese, F., Popolo, A., Parente, L., Budillon, A., & Petrella, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4725 · Cited by 63
Wang, L., Liu, R., Ye, P., Wong, C.-S., Chen, G., Zhou, P., Sakabe, K., Zheng, X., Wu, W., Zhang, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms6909 · Cited by 63
Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Feng, F. Y.-C., Brenner, J. C., Hussain, M., & Chinnaiyan, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0275 · Cited by 63
Self-citationToivanen, R., Frydenberg, M., Murphy, D., Pedersen, J., Ryan, A., Pook, D. W., Berman, D. M., BioResource, A. P. C., Taylor, R. A., & Risbridger, G. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005688 · Cited by 63
Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines
Seim, I., Jeffery, P. L., Thomas, P. B., Nelson, C. C., & Chopin, L. K. (2017) · G3 Genes Genomes Genetics · doi:10.1534/g3.117.039909 · Cited by 63
Shi, S., Wang, L., Han, D., Wu, J., Jiao, D., Zhang, K.-L., Chen, J., Li, Y., Yang, F., Zhang, J., et al. (2019) · Theranostics · doi:10.7150/thno.29884 · Cited by 63
NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes
An, Ö., Pendino, V., D’Antonio, M., Ratti, E., Gentilini, M., & Ciccarelli, F. D. (2014) · Database · doi:10.1093/database/bau015 · Cited by 63
Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer
Mendonca, J., Sharma, A. R., Kim, H.-S., Hammers, H. J., Meeker, A. K., Marzo, A. D., Carducci, M. A., Kauffman, M. G., Shacham, S., & Kachhap, S. K. (2014) · Oncotarget · doi:10.18632/oncotarget.2174 · Cited by 62
Ojo, D., Lin, X., Wong, N., Gu, Y. J., & Tang, D. (2015) · Cancers · doi:10.3390/cancers7040890 · Cited by 64
AR-V7 and prostate cancer: The watershed for treatment selection?
Ciccarese, C., Santoni, M., Brunelli, M., Buti, S., Modena, A., Nabissi, M., Artibani, W., Martignoni, G., Montironi, R., Tortora, G., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.003 · Cited by 63
SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression
Ma, J., Chang, K. S., Peng, J., Shi, Q., Gan, H., Gao, K., Feng, K. M., Xu, F., Zhang, H., Dai, B., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0809-0 · Cited by 62
PARP‐1 regulates DNA repair factor availability
Schiewer, M. J., Mandigo, A. C., Gordon, N., Huang, F., Gaur, S., de Leeuw, R., Zhao, S. G., Evans, J. R., Han, S., Parsons, T., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708816 · Cited by 63
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer
Taavitsainen, S., Annala, M., Ledet, E. M., Beja, K., Miller, P. J., Moses, M. W., Nykter, M., Chi, K. N., Sartor, O. A., & Wyatt, A. W. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00014 · Cited by 64
Dai, S., Qu, L., Li, J., & Chen, Y. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab807 · Cited by 63
Katoh, M. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1033409 · Cited by 65
New agents for prostate cancer
Agarwal, N., Lorenzo, G. D., Sonpavde, G., & Joaquim Bellmunt, B. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu038 · Cited by 65
Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications
Deng, Q., & Tang, D. G. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0217 · Cited by 64
Jeter, C. R., Liu, B., Lu, Y., Chao, H., Zhang, D., Liu, X., Chen, X., Li, Q., Rycaj, K., Calhoun‐Davis, T., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.41 · Cited by 61
Torquato, S., Pallavajjala, A., Goldstein, A., Toro, P. V., Silberstein, J. L., Lee, J., Nakazawa, M., Waters, I. G., Chu, D. T. W., Shinn, D., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00227 · Cited by 60
Androgen receptor-binding sites are highly mutated in prostate cancer
Morova, T., McNeill, D. R., Lallous, N., Gönen, M., Dalal, K., Wilson, D. M., Gürsoy, A., Keskin, Ö., & Lack, N. A. (2020) · Nature Communications · doi:10.1038/s41467-020-14644-y · Cited by 65
Essential Role for Dnmt1 in the Prevention and Maintenance of MYC-Induced T-Cell Lymphomas
Peters, S. L., Hlady, R. A., Opavska, J., Klinkebiel, D. L., Nováková, S., Smith, L. M., Lewis, R. E., Karpf, A. R., Simpson, M. A., Wu, L., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00776-13 · Cited by 61
Cao, Q., Song, Z., Ruan, H., Wang, C., Yang, X. W., Bao, L., Wang, K., Cheng, G., Xu, T., Xiao, W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0396 · Cited by 61
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
Moschini, M., Spahn, M., Mattei, A., Cheville, J. C., & Karnes, R. J. (2016) · BMC Medicine · doi:10.1186/s12916-016-0613-7 · Cited by 59
Ma, J., Bai, J., Zhang, H., Jia, J., Shi, Q., Yang, C., Wang, X., He, D., & Guo, P. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2671-1 · Cited by 61
Constitutive Activity of the Androgen Receptor
Chan, S. C., & Dehm, S. M. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-417197-8.00011-0 · Cited by 62
Kaushik, A., Vareed, S. K., Basu, S., Putluri, V., Putluri, N., Panzitt, K., Brennan, C. A., Chinnaiyan, A. M., Vergara, I. A., Erho, N., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr401106h · Cited by 59
Self-citationSomatic Alterations Contributing to Metastasis of a Castration-Resistant Prostate Cancer
Nickerson, M. L., Im, K. M., Misner, K., Tan, W., Lou, H., Gold, B., Wells, D. W., Bravo, H. C., Fredrikson, K. M., Harkins, T. T., et al. (2013) · Human Mutation · doi:10.1002/humu.22346 · Cited by 59
Focal cryotherapy of localized prostate cancer: a systematic review of the literature
Shah, T. T., Ahmed, H. U., Kanthabalan, A., Lau, B. S. T., Ghei, M., Maraj, B. H., & Arya, M. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.965687 · Cited by 59
UTX coordinates steroid hormone-mediated autophagy and cell death
Denton, D., Aung-Htut, M. T., Lorensuhewa, N., Nicolson, S., Zhu, W., Mills, K., Cakouros, D., Bergmann, A., & Kumar, S. (2013) · Nature Communications · doi:10.1038/ncomms3916 · Cited by 58
Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel
Amaro, A. A., Esposito, A. I., Gallina, A. M., Nees, M., Angelini, G., Albini, A., & Pfeffer, U. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9470-4 · Cited by 58
Concepts in solid tumor evolution
Sidow, A., & Spies, N. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.02.001 · Cited by 60
AR-v7 protein expression is regulated by protein kinase and phosphatase
Li, Y., Xie, N., Gleave, M. E., Rennie, P. S., & Dong, X. (2015) · Oncotarget · doi:10.18632/oncotarget.5608 · Cited by 58
RetractedStockley, J., Markert, E. K., Zhou, Y., Robson, C. N., Elliott, D. J., Lindberg, J., Leung, H. Y., & Rajan, P. (2015) · Scientific Reports · doi:10.1038/srep13426 · Cited by 58
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment
Ferroni, C., Pepe, A., Kim, Y. S., Lee, S., Guerrini, A., Parenti, M. D., Tesei, A., Zamagni, A., Cortesi, M., Zaffaroni, N., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00105 · Cited by 58
The Genomics of Prostate Cancer: emerging understanding with technologic advances
Rubin, M. A., & Demichelis, F. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.166 · Cited by 59
Shaw, J., Leveridge, M., Norling, C., Karén, J., Molina, D. M., O’Neill, D. J., Dowling, J. E., Davey, P. R. J., Cowan, S., Dabrowski, M. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18650-x · Cited by 58
Sun, X., Liu, X., Xia, M., Shao, Y., & Zhang, X. D. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1908-1 · Cited by 58
DNA Damage Response in Prostate CancerPreprint
Schiewer, M. J., & Knudsen, K. E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030486 · Cited by 58
Palmbos, P. L., Daignault‐Newton, S., Tomlins, S. A., Agarwal, N., Twardowski, P. W., Morgans, A. K., Kelly, W. K., Arora, V. K., Antonarakis, E. S., Siddiqui, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0024 · Cited by 58
Self-citationCui, W., Qian, Y., Zhou, X., Lin, Y., Jiang, J., Chen, J., Zhao, Z., & Shen, B. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s7-s3 · Cited by 57
EZH 2: an emerging role in melanoma biology and strategies for targeted therapy
Tiffen, J. C., Gallagher, S. J., & Hersey, P. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12280 · Cited by 58
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer
Liao, L., Testa, J. R., & Yang, H. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.02.008 · Cited by 58
Molecular landscape of prostate cancer: Implications for current clinical trials
Khemlina, G., Ikeda, S., & Kurzrock, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.001 · Cited by 62
Prostate Cancer Stem Cells: Research Advances
Jaworska, D., Król, W., & Szliszka, E. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126036 · Cited by 59
Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target
Asim, M., Massie, C. E., Orafidiya, F. A., Pértega‐Gomes, N., Warren, A. Y., Esmaeili, M., Selth, L. A., Zecchini, H. I., Luko, K., Qureshi, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv371 · Cited by 58
The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p
Towers, C. G., Guarnieri, A. L., Micalizzi, D. S., Harrell, J. C., Gillen, A. E., Kim, J., Wang, C.-A., Oliphant, M. U. J., Drasin, D. J., Guney, M. A., et al. (2015) · Nature Communications · doi:10.1038/ncomms10077 · Cited by 57
Tseng, J., Lin, C., Liang-Chen, S., Fu, H., Yang, S., & Chuu, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9380 · Cited by 57
Hu, Q., Zhang, B., Chen, R., Fu, C., Jun, A., Fu, X., Li, J., Fu, L., Zhang, Z., & Dong, J. (2019) · Oncogenesis · doi:10.1038/s41389-019-0138-y · Cited by 57
Li, W., Bai, X., Li, J., Zhao, Y., Liu, J., Zhao, H., Liu, L., Ding, M., Wang, Q., Shi, F., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0388-0 · Cited by 58
Dessai, A. S., Domínguez, M. P., Chen, U.-I., Hasper, J., Prechtl, C., Yu, C. R., Katsuta, E., Dai, T., Zhu, B., Jung, S. Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1708 · Cited by 59
Li, X., Wang, Y., Deng, S., Zhu, G., Wang, C., Johnson, N. A., Zhang, Z., Tirado, C. R., Xu, Y., Metang, L. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.010 · Cited by 61
Metadata
- Authors
- Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., Asangani, I. A., Ateeq, B., Chun, S. Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J. R., Palanisamy, N., Ryslik, G. A., Vandin, F., Raphael, B. J., Kunju, L. P., Rhodes, D. R., Pienta, K. J., Chinnaiyan, A. M., & Tomlins, S. A.
- Affiliations
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- Yale University (US)
- Brown University (US)
- Corresponding author
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- ORCID
- Grasso, Catherine S.
- Robinson, Dan R.
- Cao, Xuhong
- Dhanasekaran, Saravana M.
- Khan, Amjad P.
- Jing, Xiaojun
- Brenner, J. Chad
- Asangani, Irfan A.
- Ateeq, Bushra
- Siddiqui, Javed
- Mehra, Rohit
- Prensner, John R.
- Palanisamy, Nallasivam
- Ryslik, Gregory A.
- Vandin, Fabio
- Raphael, Benjamin J.
- Kunju, Lakshmi P.
- Rhodes, Daniel R.
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- Tomlins, Scott A.
- Venue
- Nature
- Published
- 2012-05-20
- Volume
- 487
- Issue
- 7406
- Pages
- 239-243
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3396711
- OpenAlex
- W2051025382
- Cited by
- 2,517
- References
- 23
- Citations by year
- 2026: 75 · 2025: 128 · 2024: 136 · 2023: 181 · 2022: 178 · 2021: 199 · 2020: 233 · 2019: 193 · 2018: 205 · 2017: 195 · 2016: 194 · 2015: 212 · 2014: 177 · 2013: 169 · 2012: 33
- FWCI
- 152.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca013287-14)
- National Cancer Institute (P50-CA-69568, R01CA132874, U01CA111275, R01CA13287, P50CA069568, T32CA140044, P30CA046592, T32CA009676, U01CA113913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, somatic mutations, copy number alterations, chromatin modifiers, androgen receptor, FOXA1, KMT2D, TMPRSS2-ERG fusion, PTEN loss, androgen receptor amplification, chromosomal rearrangements
- MeSH terms
- Cells, Cultured, Humans, Male, Molecular Sequence Data, Mutation, Orchiectomy, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Sequence Alignment, Cell Proliferation, Hepatocyte Nuclear Factor 3-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
